Negaban (temocillin) / Eumedica - LARVOL DELTA

Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales? (PubMed, J Antimicrob Chemother) - "This study demonstrated the high in vitro efficacy of temocillin against 3GC-R Enterobacterales from BJIs, regardless of the underlying resistance mechanism. However, dosage adjustments based on the strain's MIC and the patient's renal function are crucial for optimal efficacy."

Journal • Infectious Disease

Temocillin vs carbapenems for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales: DOOR and subgroups analysis of ASTARTÉ pragmatic trial (ESCMID Global 2026) - No abstract available

In vitro activity of temocillin alone and in combination with avibactam against carbepenemase-producing Klebsiella pneumoniae strains (ESCMID Global 2026) - No abstract available

Combination therapy • Preclinical • Infectious Disease • Pneumonia

Exploring carbapenem-sparing strategies: in vitro susceptibility analysis of temocillin and cefepime against Enterobacterales bloodstream isolates (ESCMID Global 2026) - No abstract available

Preclinical

Head-to-head in vitro susceptibility comparison of temocillin with co-amoxiclav, piperacillin/tazobactam and meropenem among Enterobacterales isolates in a UK district general hospital (ESCMID Global 2026) - No abstract available

Head-to-Head • Preclinical

In vitro activity of temocillin alone and in combination with amikacin against MDR K. pneumoniae strains: reversal of phenotypic resistance (ESCMID Global 2026) - No abstract available

Combination therapy • Preclinical • Infectious Disease • Pneumonia

Investigating temocillin resistance amongst Gram-negative isolates from renal patients within a tertiary London teaching hospital (ESCMID Global 2026) - No abstract available

Clinical • Gram negative • Infectious Disease

Evaluation of MIC and clinical response to temocillin in a university transplant centre (ESCMID Global 2026) - No abstract available

Clinical • Transplantation

Synergistic activity of fosfomycin and temocillin against GES carbapenemase-producing Enterobacteriaceae (ESCMID Global 2026) - No abstract available

Pharmacodynamics of temocillin: fT>MIC targets from an in vitro pharmacokinetic model of infection in comparison to murine thigh and lung infection models (ESCMID Global 2026) - No abstract available

PK/PD data • Preclinical • Infectious Disease • Respiratory Diseases

Pharmacokinetic modelling of temocillin in children with urinary tract infections (ESCMID Global 2026) - No abstract available

Clinical • PK/PD data • Infectious Disease • Nephrology

Temocillin for Gram-negative infections - clinical evidence (ESCMID Global 2026) - "Organised by Eumedica SA"

Clinical • Gram negative • Infectious Disease

Temocillin under the microscope - "Start smart then focus" (ESCMID Global 2026) - "Organised by Eumedica SA"

IS30 - Replacing broad with smart: temocillin strikes again (ESCMID Global 2026) - "- Core principles of AMS, including the "Start Smart Then Focus" approach, and how AST and PK/PD profiling support evidence-based decision-making in the use of temocillin. - A review of recent clinical and microbiological data on temocillin, including: a) Its non-inferiority to carbapenems in the treatment of bacteraemia due to 3GCR-Enterobacterales; b) Its superiority to cephalosporins in preserving the intestinal microbiota in the management of febrile UTI"

Infectious Disease • Septic Shock

PK/PD-based optimisation of temocillin dosing for the treatment of complicated urinary tract infections in non-ICU patients according to their renal function (ESCMID Global 2026) - No abstract available

Clinical • PK/PD data • Infectious Disease • Nephrology

Comment on: Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched-cohort study. (PubMed, J Antimicrob Chemother) - No abstract available

Journal • Retrospective data • Infectious Disease • Nephrology

Mapping Escherichia coli in Women with Simple Urinary Tract Infections: Phenotypic ESBL/AmpC Screening and Whole-Genome Insights from Oman. (PubMed, Antibiotics (Basel)) - "coli showed high susceptibility to nitrofurantoin (~97%), carbapenems, aminoglycosides, and piperacillin-tazobactam, but reduced susceptibility to cephalosporins, fluoroquinolones, cotrimoxazole, and ampicillin. Nitrofurantoin, mecillinam, fosfomycin, temocillin, and nitroxoline would be effective carbapenem-sparing oral options. Continuous phenotypic and genomic surveillance are crucial to guide antimicrobial therapy and stewardship."

Journal • Infectious Disease • Nephrology • Pneumonia

Temocillin for non-urinary tract infections caused by AmpC-producing Enterobacterales: Is it a feasible option? (PubMed, Infect Dis Now) - "Having led to favorable outcomes, temocillin may represent a carbapenem-sparing option when in vitro susceptibility is confirmed. These findings call for further evaluation in larger prospective clinical studies."

Journal • Critical care • Infectious Disease • Nephrology

Susceptibility Studies of Novel Antimicrobial Drugs Against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae. (PubMed, J Evid Based Med) - "Cefiderocol appears highly promising as a therapy for CR-hvKP infections. Our findings will not only effectively address the challenge of CR-hvKP resistance, but also provide evidence to support the optimization of clinical therapeutic strategies and further promote the development and application of novel antimicrobial drugs."

Journal • Infectious Disease • Pneumonia

ASTARTÉ: Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins (clinicaltrials.gov) - P3 | N=334 | Completed | Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Recruiting ➔ Completed

Trial completion

Pharmacokinetic/pharmacodynamic optimization of temocillin treatment against CTX-M-15-producing Klebsiella pneumoniae isolates in a hollow-fiber infection model. (PubMed, Antimicrob Agents Chemother) - "While both regimens demonstrated initial bactericidal activity, CI was more effective in sustaining bacterial suppression and limiting resistance emergence. These findings support the potential clinical benefit of CI for treating infections caused by CTX-M-15-producing K. pneumoniae and warrant further clinical validation."

Journal • PK/PD data • Infectious Disease • Pneumonia

Method validation for the detection of multidrug-resistant Enterobacterales in hospital aquatic environment. (PubMed, J Hosp Infect) - "These results suggest that for the detection of multidrug-resistant pathogens in the hospital aquatic environment, swabbing of sink P-traps and water collection from toilets combined with enrichment are the most suitable methods."

Journal

Adaptation and performance evaluation of the French society of microbiology algorithm for detection of carbapenemase-producing enterobacterales using VITEK2 antibiotic susceptibility testing system. (PubMed, Eur J Clin Microbiol Infect Dis) - "The adapted CA-SFM algorithm offers enhanced detection of CPE, particularly for OXA-48-like strains with weak carbapenem hydrolysis, which are often missed by carbapenem MIC-based methods alone. Given the clinical risks of under-detection and transmission, implementing the adapted CA-SFM algorithm strategy could strengthen infection control and antimicrobial stewardship efforts."

Journal • Infectious Disease

Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study. (PubMed, J Antimicrob Chemother) - "In this study, compared with other beta-lactams, temocillin was not associated with an increased risk of early clinical failure in the treatment of 3GC-R Enterobacterales UTIs."

Journal • Retrospective data • Infectious Disease • Nephrology

Temocillin: A Narrative Review of Its Clinical Reappraisal. (PubMed, Antibiotics (Basel)) - "It also exhibits synergistic activity with agents like fosfomycin, further enhancing its clinical value. Most of the current evidence is derived from retrospective and observational studies. Temocillin emerges as a promising carbapenem-sparing option for the treatment of challenging infections caused by multidrug-resistant Gram-negative bacteria."

Journal • Review • Infectious Disease • Nephrology • Pediatrics • Pneumonia • Respiratory Diseases